Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Polycystic Ovary Syndrome 13Insulin Resistance 3Hyperandrogenism 3Metabolic Syndrome 2Solid Tumors 1Primary Dysautonomias 1Overweight 1Motor Activity 1Menstruation Disturbances 1Infertility 1Hirsutism 1Endometrial Neoplasms 1Depression 1Breast Neoplasms 1Bipolar Disorder 1Anxiety Disorders 1Advanced Malignancies 1

Interventions

Trastuzumab 594Paclitaxel 561Cyclophosphamide 545Docetaxel 478Capecitabine 387Letrozole 350Fulvestrant 310Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 175Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Ethinyl Estradiol × Clear all
NCT00193726 2018-09-20

Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer

Tata Memorial Hospital

Phase 3 Terminated
273 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡